Application of NK cell exosome combined with NK cells in treatment of triple negative breast cancer

Through the combined application of NK cell exosomes and NK cells, the problem of poor chemotherapy effect and lack of targeted treatment for triple-negative breast cancer is solved, and effective inhibition and safe tumor-targeted treatment for triple-negative breast cancer is achieved.

CN118987031APending Publication Date: 2024-11-22XINJIANG WESTERN SAIAO BIOTECHNOLOGY CO LTD
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411107338.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-13
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

The poor chemotherapy effect of triple-negative breast cancer, lack of clear targets for targeted treatment, poor immunogenicity and low safety of cellular immunotherapy, lead to difficulties in treatment.

Method used

The combination of NK cell exosomes (NK-Exos) and NK cells is used to introduce them into the body through intravenous injection and other channels. The ratio and treatment course of the compounds are designed to target the treatment of triple-negative breast cancer.

Benefits of technology

It significantly inhibits the proliferation and apoptosis of tumor cells, improves the killing ability of tumors, and shows safety and significant tumor suppression effects in mice, without obvious in vivo toxicity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118987031A_ABST
    Figure CN118987031A_ABST
Patent Text Reader

Abstract

The invention discloses application of NK cell exosome combined with NK cells in treatment of triple negative breast cancer, creatively attempts to use a scheme of NK-Exos combined with NK cells to treat triple negative breast cancer, and in-vitro and in-vivo experiments prove that combined application of NK-Exos and NK cells can significantly inhibit growth of tumors and is safe in mice.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biotechnology and relates to the application of NK cell exosomes combined with NK cells in the treatment of triple-negative breast cancer. Background Art

[0002] Breast cancer is a disease in which abnormal breast cells grow out of control and form tumors. If not controlled, the tumors will spread throughout the body and be fatal. Triple-negative breast cancer accounts for 20% of all breast cancers. It is highly invasive, easily metastatic, and has a very poor prognosis. It can be said to be the most "toxic" subtype of breast cancer, and there are many difficulties in its treatment. Triple-negative breast refers to breast cancer tissues whose immunohistochemical examination results show that estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (Her-2) are all negative. Because triple-negative breast cancer lacks the expression of ER, PR, and Her-2, there are fewer targeted drugs for triple-negative breast cancer, and endocrine therapy and targeted therapy for Her-2 have no effect on triple-negative breast cancer. Although triple-negative breast cancer is sensitive to chemotherapy, usually only about 20% of patients have a good chemotherapy effect, so more effective treatments are needed.

[0003] At present, the treatment of breast cancer has entered the era of molecular classification, and effective therapeutic targets have been found for some subtypes. For example, anti-Her-2 targeted therapy for Her-2 positive breast cancer and anti-hormone endocrine therapy for endocrine hormone receptor positive breast cancer, but triple negative breast cancer lacks clear therapeutic targets, and chemotherapy is the main treatment. In recent years, a new generation of immunotherapy using NK cells, cytotoxic CD8+T lymphocytes or macrophages has been developed to achieve tumor-specific targeting and avoid adverse reactions. However, the progress of cell-based immunotherapy has been hindered by the combined effects of the tumor microenvironment and tumor-derived extracellular vesicles, which reduces the immunogenicity of cancer cells. Exosomes are membrane vesicles released into the extracellular matrix after the fusion of intracellular multivesicular bodies (MVBs) with the cell membrane. It is a nanoscale lipid inclusion structure with a diameter of 30-100 nm, which contains substances such as proteins, mRNA and miRNA. Exosomes have been shown to be involved in immune responses, viral pathogenicity, pregnancy, cardiovascular disease, central nervous system-related diseases and cancer progression. NK cell-derived exosomes (NK-Exos) are vesicles released from NK cells through exocytosis. NK-Exos have similar cell-killing properties to NK cells, contain a variety of cytotoxic proteins (perforin, granzyme, granulysin, etc.), miRNA and cytokines, etc., can induce tumor cell apoptosis, and play an important role in the treatment of tumors. However, it is regrettable that there are currently few studies on NK-Exos in breast cancer, and the application effect and mechanism of action in breast cancer are still unclear, and further experiments are needed to explore. Summary of the invention

[0004] In order to solve the problems of poor chemotherapy effect, lack of clear therapeutic targets, poor immunogenicity and low safety of cellular immunotherapy in the existing technology for the treatment of triple-negative breast cancer, achieve tumor-specific targeting and avoid adverse reactions, and provide new directions and solutions for the clinical treatment of triple-negative breast cancer.

[0005] The present invention provides the use of NK cell exosomes (NK-Exos) combined with NK cells in preparing a pharmaceutical composition for preventing or treating triple-negative breast cancer.

[0006] Furthermore, the NK cell exosomes are administered orally, via suppository, around lesions, on lesion surfaces, topically, intravenously, parenterally, intraperitoneally, intramuscularly, intralesionally, intrathecally, intranasally, or subcutaneously.

[0007] Furthermore, the NK cells are administered orally, via suppository, around lesions, on the surface of lesions, topically, intravenously, parenterally, intraperitoneally, intramuscularly, intralesionally, intrathecally, intranasally, or subcutaneously.

[0008] Furthermore, the NK cell exosomes are administered by intravenous injection.

[0009] Furthermore, the NK cells are administered by intravenous injection.

[0010] In some embodiments, the "administration" involves the actual physical introduction of the agent into or onto the target biological target (e.g., host and / or subject) (where appropriate). The composition can be applied to cells in vitro or in vivo (e.g., "contact"). The composition can be applied to a subject in vivo via an appropriate route of administration. Any and all methods of introducing the composition into a host are contemplated according to the present invention. The method does not depend on any particular mode of introduction and should not be interpreted as such. The mode of introduction is well known to those skilled in the art and is also exemplified herein. The term includes routes of administration that allow the agent to perform its intended function. Examples of routes of administration that can be used to treat the body include injection (subcutaneous, intravenous, parenteral, intraperitoneal, intrathecal, etc.), oral, inhalation, and transdermal routes. The injection may be a bolus or may be a continuous infusion. Depending on the route of administration, the agent may be coated or arranged in a selected material to protect it from natural conditions that may adversely affect its ability to perform its intended function. The agent may be administered alone or in combination with a pharmaceutically acceptable carrier. The agent may also be administered as a prodrug, which is converted into its active form in vivo.

[0011] Furthermore, the ratio of NK cell exosomes to NK cells is 100 μg: (1×10 4 -1×10 7 )indivual.

[0012] In some embodiments, the ratio of NK cell exosomes to NK cells is 100 μg: 1×10 4 pcs, 100μg: 1×10 5 pcs, 100μg: 1×10 6 pcs, 100μg: 1×10 7 indivual.

[0013] Furthermore, the pharmaceutical composition is used for prevention or treatment according to a course of treatment.

[0014] Furthermore, the treatment course includes one injection of NK cell exosomes and one injection of NK cells as one course of treatment.

[0015] Furthermore, the treatment course needs to be more than 5 times.

[0016] Furthermore, the injection of NK cell exosomes and NK cells is performed alternately.

[0017] Furthermore, the time interval between the two injections was 3 days.

[0018] In some embodiments, the interval between the use of the NK cell exosomes and the NK cells is 3 days, that is, the NK cells are administered 72 hours after the use of the NK cell exosomes. In some embodiments, each use of the NK cell exosomes and NK cells requires intravenous injection. In some embodiments, the combined use of the NK cell exosomes and NK cells needs to be repeated more than 5 times. In some embodiments, the combined application of the NK cell exosomes and NK cells is repeated 5 times.

[0019] Furthermore, the triple-negative breast cancer is from a human and / or non-human individual.

[0020] Furthermore, the triple-negative breast cancer is from human.

[0021] In some embodiments, the NK cells are obtained by directed induction culture of healthy human peripheral blood mononuclear cells. In some embodiments, the NK cell exosomes are obtained by ultracentrifugation of NK cell culture supernatant.

[0022] The term "NK cell" used in the present invention refers to the administration of NK cells and / or NK-like T cells to a patient. The patient may suffer from a malignant disease (such as breast cancer) or a patient in need of such therapy. In some embodiments, the NK cell therapy refers to a cell therapy in which the substance as the active ingredient is a NK cell. Such NK cells may be allogeneic or autologous. In a specific embodiment, NK cells can be genetically engineered by knocking out or knocking in a specific gene. In some embodiments, the NK cells include NK cells expressing chimeric antigen receptors. In some embodiments, the NK cells may have been expanded or purified in vitro. In some embodiments, the NK cells may be included in a composition of other blood cells, such as other cells of the immune system. The terms "NK cells", "memory NK cells", "natural killer cells", "natural killer (NK) cells", "NK", etc. are used interchangeably to refer to a class of major immune effector cells that protect the body from viral infection and tumor cell invasion through non-antigen-specific pathways. New functions may be acquired by engineered (genetically modified) NK cells, including the ability to specifically recognize tumor antigens and having enhanced anti-tumor cytotoxic effects.

[0023] In some embodiments, the "treatment" refers to the improvement, prevention, or reversal of a disease or condition or at least one distinguishable symptom thereof. In certain specific embodiments, the "treatment" refers to the improvement, prevention, or reversal of at least one measurable physiological parameter associated with the disease or condition to be treated, which parameter is not necessarily recognizable in mammals or recognized by mammals. In some embodiments, the "treatment" refers to the inhibition or reduction of a disease or disease process, which can be physical, such as certain distinguishable adverse symptoms; such inhibition or reduction can be physiological, such as stabilizing physiological parameters; such inhibition or reduction can be both.

[0024] The present invention provides a pharmaceutical composition, which comprises a preventive effective amount or a therapeutic effective amount of NK cell exosomes and NK cells in the above application.

[0025] Furthermore, the pharmaceutical composition also includes a pharmaceutical adjuvant.

[0026] Furthermore, the auxiliary agent includes excipients, diluents or other liquid solvents, dispersing aids, suspending aids, surfactants, isotonic agents, thickeners, emulsifiers, preservatives, solid binders, and lubricants.

[0027] In some embodiments, the excipients added to the pharmaceutical composition include but are not limited to: diluents, excipients such as lactose, sodium chloride, glucose, urea, starch, water, etc., fillers such as starch, sucrose, etc.; binders such as monosyrup, glucose solution, starch solution, cellulose derivatives, alginate, gelatin and polyvinyl pyrrolidone; wetting agents such as glycerol; disintegrants such as dry starch, sodium alginate, kelp polysaccharide powder, agar powder, calcium carbonate and sodium bicarbonate; absorption promoters quaternary ammonium compounds, sodium lauryl sulfate, etc.; surfactants such as polyoxyethylene sorbitan fatty acid esters, sodium lauryl sulfate, stearic acid monoglyceride, hexadecanol, etc.; wetting agents such as glycerol, starch, etc.; adsorption carriers such as starch, lactose, bentonite, silica gel, kaolin and soap clay, etc.; lubricants such as talc, calcium and magnesium stearate, polyethylene glycol, boric acid powder, etc.

[0028] In some embodiments, the adjuvant may be any one or more of the adjuvants listed herein. The addition of the adjuvant allows the pharmaceutical composition to be used in an acceptable form, and the preferred acceptable form is an injection solution.

[0029] The term "therapeutically effective amount" as used herein relates to an amount of a drug or material, a composition or dosage form containing a drug that is effective in producing some desired therapeutic effect and matched with a reasonable benefit / risk ratio when administered according to a desired treatment regimen. In some embodiments, the therapeutically effective amount is an amount of the drug that effectively prevents, alleviates or ameliorates the symptoms of a disease or prolongs the survival of the subject to be treated. The dosage will be adjusted to individual needs in each specific case, including the specific drug administered, the route of administration, the condition being treated, and the patient being treated.

[0030] The present invention provides a drug kit, which comprises: NK cell exosomes and NK cells in the above-mentioned application.

[0031] Furthermore, the medicine kit also includes instructions for use.

[0032] Furthermore, the instructions for use indicate the combined use of NK cell exosomes and NK cells.

[0033] Furthermore, the instructions for use indicate whether the NK cell exosomes and NK cells are administered simultaneously, separately, at intervals, or sequentially.

[0034] In some embodiments, the combined use of NK cell exosomes and NK cells can be used as a disease prevention measure, and in this measure can be used to treat some malignant diseases, such as breast cancer.

[0035] In some embodiments, the NK cell exosomes and NK cells can be used at the same time, continuously or at intervals. In some embodiments, the NK cell exosomes and NK cells have limited / unlimited concentrations.

[0036] The term "prevention" used in the present invention refers to reducing the risk of acquiring a certain disease or condition by administering in advance, and may also refer to maintaining or reversing the condition of a disease that was originally about to worsen, and preventing the deterioration of the condition, even if the symptoms of the disease have not yet appeared.

[0037] The present invention provides the use of NK cell exosomes and NK cells in the aforementioned application in preparing a product for inhibiting triple-negative breast cancer cells or tissues and promoting apoptosis of triple-negative breast cancer cells.

[0038] The present invention provides the use of NK cell exosomes and NK cells in preparing a product for improving the inhibitory or killing ability of NK cells on breast cancer.

[0039] Furthermore, the breast cancer includes triple-negative breast cancer.

[0040] The term "killing ability" used in the present invention refers to killing cells by contacting the cells with an effective amount of antibodies, T cells, NK cells, immunoconjugates, bispecific / multispecific molecules or compositions. For example, the NK cells and NK cell exosomes of the present application can enhance the killing ability of tumor cells.

[0041] The present invention provides an in vitro non-therapeutic method for inhibiting triple-negative breast cancer cells or tissues, the method comprising the step of applying the aforementioned pharmaceutical composition or the aforementioned drug kit to in vitro triple-negative breast cancer cells or tissues.

[0042] The present invention provides a method for detecting the inhibition rate of triple-negative breast cancer cells, the method comprising:

[0043] DMEM medium was first added to the RTCA test plate containing triple-negative breast cell lines to determine the background impedance value, and the logarithmic phase cells were collected to adjust the cell suspension to add 8,000 cells to the test plate, and then the test plate was left to stand at room temperature. When the cells sank to the bottom of the test plate, the test plate was placed on a powered test bench for real-time dynamic cell proliferation detection. When the cells proliferated to an Index value close to 1, NK cells + NK-Exos were added to the culture wells, and real-time dynamic detection was performed until the growth curve of more than 72 hours after intervention. The inhibition rate at 24 hours, 48 ​​hours, and 72 hours was calculated, and the cell effect curve under the action of NK-Exos and NK cells was analyzed;

[0044] Logarithmic phase cells were collected and adjusted to a cell suspension of 8,000 cells, added to the well plate, and placed in an incubator. When the cell fusion rate was about 60% to 70%, NK cells + NK-Exos were added to the culture wells. At 48 h after the intervention, CCK-8 detection reagent was added to the wells. After incubation at 37°C for 4 h, the absorbance at 450 nm was measured with a microplate reader, and the cell inhibition rate was calculated: inhibition rate (%) = (OD value of the control group - OD value of the experimental group / OD value of the control group) × 100%.

[0045] Furthermore, the amount of NK cells + NK-Exos added was 1×10 4 NK+10μg NK-Exo / well.

[0046] Advantages and beneficial effects of the present invention:

[0047] The purpose of the present invention is to solve the problems in the prior art of triple-negative breast cancer treatment, such as poor chemotherapy effect, lack of clear therapeutic targets in targeted therapy, poor immunogenicity and low safety of cellular immunotherapy, achieve tumor-specific targeting and avoid adverse reactions, and provide a new direction and solution for the clinical treatment of triple-negative breast cancer.

[0048] (1) NK-Exos affect the capture and killing of tumor cells by immune cells, which also suggests that NK-Exos may not only be used as a single treatment method, but also as an auxiliary method for NK cell therapy. Its combined use with NK cells can enhance the efficacy of cell therapy.

[0049] (2) NK-Exos mainly accumulated in the liver of tumor-free mice, and showed significantly high uptake and accumulation in the liver and target tumors of breast cancer-bearing mice.

[0050] (3) The inhibitory effect of NK-Exos combined with NK cells on tumors was better than that of NK cell therapy alone and did not cause significant in vivo toxicity.

[0051] This application pioneered the use of NK-Exos combined with NK cells to treat triple-negative breast cancer. Combined in vitro and in vivo experiments proved that the combined use of NK-Exos and NK cells can significantly inhibit tumor growth and is safe in mice. BRIEF DESCRIPTION OF THE DRAWINGS

[0052] Figure 1 The RTCA results of NK-Exos combined with NK cells in MDA-MB-231. A: Real-time cell proliferation curves of cells in each group. The arrows indicate the intervention time of NK-Exos or NK. B: Cell inhibition rate of cells in each group at 24 h, 48 h and 72 h. Experimental data are expressed as Mean ± SEM, n = 3, *P < 0.05, **P < 0.01. Figure 2 The CCK-8 results of the survival rate of MDA-MB-231 cells after NK-Exos combined with NK cells intervention at 48 h. The experimental data are expressed as Mean±SEM, n=3, *P<0.05, **P<0.01.

[0053] Figure 3 These are IVIS imaging images of nude mice. A: In vivo fluorescence images of nude mice at 4 h, 8 h, and 24 h after injection of Dil-NK-Exos. B: In vitro fluorescence images of nude mice at 24 h after injection of Dil-NK-Exos. n=3.

[0054] Figure 4The therapeutic effect of NK-Exos combined with NK cells in breast cancer nude mice. A: Tumor volume change curve of nude mice in PBS group. B: Tumor volume change curve of nude mice in NK cell group. C: Tumor volume change curve of nude mice in NK-Exos+NK cell group. D: Change curve of the average tumor volume of three groups of nude mice. E: In vitro tumor images of three groups of mice after treatment. F: In vitro tumor weight of three groups after treatment. Experimental data are expressed as Mean±SEM, n=6, *P<0.05, **P<0.01.

[0055] Figure 5 The weight and staining results of nude mice with breast cancer in different groups; A: The average weight change curve of nude mice in each group. B: H&E staining pictures of nude mice tumors in each group. Experimental data are expressed as Mean ± SEM, n = 6.

[0056] Figure 6 The safety of NK-Exos combined with NK cells in the treatment of breast cancer in nude mice. A: In vitro images of nude mouse livers in each group. B: Weight of nude mouse livers in each group. C: Weight of nude mouse hearts in each group. D: Weight of nude mouse spleens in each group. E: Weight of nude mouse lungs in each group. F: Weight of nude mouse kidneys in each group. G: H&E staining images of nude mouse heart, liver, spleen, lungs, and kidneys in each group. Experimental data are expressed as Mean±SEM, n=6. DETAILED DESCRIPTION

[0057] The present invention will be described in detail below in conjunction with the accompanying drawings and embodiments, so that those skilled in the art can understand and implement the present invention and further recognize the advantages of the present invention.

[0058] Example 1

[0059] 1. Experimental Materials

[0060] The sources of the biological samples of the present invention are shown in Table 1.

[0061] Table 1

[0062] name source Remark NK cells Obtained by directed induction culture of healthy human peripheral blood mononuclear cells NK-Exos NK cell culture supernatant was obtained by ultracentrifugation MDA-MB-231 Purchased from Punosai CL-0150B Triple negative breast cancer cell lines

[0063] The sources of the reagents of the present invention are shown in Table 2.

[0064] Table 2

[0065] name factory model Fetal bovine serum (FBS) Sigma C0239 1% Penicillin-Streptomycin Corning 30-002-CI DMEM high glucose medium DAKEWE 6016121 PBS Cytiva SH3025601 CCK-8 Kit Solarbio CA1210 Dil Dye Thermo V22887 Hematoxylin Sigma H9627 Eosin Y (water soluble) Sinopharm Group 71014544 Anhydrous ethanol Sinopharm Group 10009218 Xylene Sinopharm Group 10023418 hydrochloric acid Sinopharm Group 10011018 Paraffin embedding Sinopharm Group 69019361 Neutral gum Sinopharm Group 10004160

[0066] The sources of the instruments and equipment of the present invention are shown in Table 3.

[0067] Table 3

[0068]

[0069]

[0070] The sources of animal materials of the present invention are shown in Table 4.

[0071] Table 4

[0072] variety source Female BALB / c nude mice Beijing Weitonglihua Laboratory Animal Technology Co., Ltd.

[0073] 2. Experimental methods

[0074] The experimental method described in this application includes the following three parts:

[0075] (1): In human triple-negative breast cancer cells, verify that NK-Exos+NK cells inhibit the proliferation rate and killing ability of MDA-MB-231 (human triple-negative breast cancer cell line);

[0076] (2): Establish a nude mouse MDA-MB-231 subcutaneous transplant tumor model, and observe its homing and distribution characteristics in tumor-bearing mice by injecting fluorescein-labeled NK-Exos and performing in vivo luminescence imaging;

[0077] (3): The volume and weight of triple-negative breast cancer tumors in mice were observed by injecting NK-Exos + NK cells, and the pathological effects of NK-Exos combined with NK cell injection on the main tissues and organs of mice were evaluated.

[0078] The following is an introduction to the experimental methods in three parts:

[0079] 2.1 Verification of NK-Exos+NK cells’ ability to inhibit proliferation and kill MDA-MB-231 (human triple-negative breast cancer cell line)

[0080] S1: Successfully cultured the MDA-MB-231 human triple-negative breast cell line;

[0081] S2: First add 50 μL DMEM medium to the E-Plate16 detection plate of RTCA to determine the background impedance value, collect MDA-MB-231 logarithmic phase cells and adjust the cell suspension to 8000 cells per well to add to the E-Plate detection plate, let it stand at room temperature for 3 minutes, observe until the cells sink to the bottom of the detection plate, put the detection plate on the powered detection table for real-time dynamic cell proliferation detection, and group the cells when the cell proliferation reaches an Index value close to 1. According to the group (n=3): PBS group, NK cell group, NK-Exos group, NK-Exos+NK cell group, add 5 μL PBS, 1×10 4 NK cells / well, 10 μg NK-Exos and 1×10 4NK cells + 10 μg NK-Exos / well, and real-time dynamic detection was performed for the growth curve of more than 72 h after intervention. The inhibition rates of different groups at 24 h, 48 h, and 72 h were calculated, and the cell effect curves under the action of NK-Exos and NK cells were analyzed.

[0082] S3: Collect MDA-MB-231 cells in logarithmic phase and adjust the cell suspension to 8000 cells per well in a 96-well plate. Place the plate in an incubator and when the cell fusion rate is about 60% to 70%, group the cells. According to the group (n=3): PBS group, NK cell group, NK-Exos group, NK-Exos+NK cell group, add 5 μL PBS, 1×10 4 NK cells / well, 10 μg NK-Exo and 1×10 4 NK cells + 10 μg NK-Exo / well. At 48 h after intervention, CCK-8 detection reagent was added to each well, and the absorbance at 450 nm was measured with a microplate reader after incubation at 37°C for 4 h to calculate the cell inhibition rate: inhibition rate (%) = (control group OD value - experimental group OD value / control group OD value) × 100%.

[0083] 2.2 Fluorescein-labeled NK-Exos and in vivo luminescence imaging to observe their homing and distribution characteristics in tumor-bearing mice

[0084] S1: Six 4-week-old female nude mice were weighed and found to have no statistical difference. The mice were randomly divided into two groups, with three mice in each group. The first group of nude mice served as the healthy control group, and the second group of nude mice served as the tumor-bearing group.

[0085] S2: MDA-MB-231 tumor cells were cultured at a rate of 1×10 7 Each cell was resuspended in 100 μL PBS and inoculated subcutaneously in the axillary flank of nude mice in the tumor-bearing group;

[0086] S3: 4 weeks after tumor inoculation, subcutaneous tumors in mice reached approximately 800-1000 mm 2 The nude mice in the control group and tumor-bearing group were injected with 500 μg Dil-labeled NK-Exos via tail vein;

[0087] S4: In vivo luminescence imaging (IVIS) was performed to observe the distribution characteristics of NK-Exos in nude mice at 4 h, 8 h, and 24 h after Dil-NK-Exos injection, and images were collected. The nude mice were killed at 24 h, and the target tumors and major organs (heart, liver, spleen, lung, and kidney) were collected to detect the fluorescence intensity of NK-Exos in ex vivo tissues.

[0088] 2.3 Evaluation of the pathological effects of NK-Exos combined with NK cell injection on major tissues and organs of mice

[0089] S1: 18 4-week-old female nude mice were selected and reported to have no statistical difference;

[0090] S2: MDA-MB-231 tumor cells were cultured at a rate of 1×10 7 Each mouse was resuspended in 100 μL PBS and inoculated subcutaneously in the axillary flank of all nude mice.

[0091] S3: 4 weeks after tumor inoculation, subcutaneous tumors in mice reached approximately 800-1000 mm 2 The nude mice were randomly divided into 3 groups, with 6 nude mice in each group. The first group of nude mice served as the PBS control group, the second group of nude mice served as the NK cell group, and the third group of nude mice served as the NK-Exos+NK cell group.

[0092] S4: Each group of nude mice received a 28-day treatment regimen. The specific treatment regimen was as follows: On the 1st, 7th, 13th, 19th, and 25th days of treatment, the mice in the NK cell group and the NK-Exos+NK cell group received 1×10 NK cells. 6 On the 4th, 10th, 16th, 22nd and 28th days of treatment, mice in the NK-Exos+NK cell group received 100 μg / mouse NK-Exos tail vein injection; mice in the PBS control group received 100 μL / mouse PBS tail vein injection on each day of NK cell or NK-Exos injection. The tumor cells, NK cells and NK-Exos injections were all 100 μL of sterile injection solution resuspended in PBS.

[0093] S5: From the time of tumor inoculation, the nude mice in each group were weighed twice a week, and the tumor volume was measured twice a week until the end of the treatment described in S4;

[0094] S6: On the second day after the end of treatment, mice in each group were killed, and tumor, heart, liver, spleen, lung, and kidney samples were collected, weighed, and H&E staining was performed to analyze histopathological changes.

[0095] 3. Experimental results

[0096] 3.1NK-Exos+NK cells inhibit the proliferation rate and killing ability of MDA-MB-231 (human triple-negative breast cancer cell line)

[0097] According to the results, the RTCA results showed that the cell inhibition rate at 24 h, 48 h and 72 h proved that NK-Exos pre-intervention enhanced the inhibition rate of NK cells on tumor proliferation. The inhibition rate of NK cells on MDA-MB-231 tumor cells intervened by NK-Exos reached 87.93% at 72 h, which was significantly different from the inhibition rate of 47.51% of tumor cells intervened by NK cells alone ( Figure 1 ).

[0098] The results of CCK-8 experiments showed that the cell survival rate of tumor cells pre-intervened with NK-Exos and then given NK cell intervention for 48 hours was significantly different from that of NK cell intervention alone ( Figure 2 ).

[0099] 3.2 Fluorescein-labeled NK-Exos and in vivo luminescence imaging to observe their homing and distribution characteristics in tumor-bearing mice

[0100] In vivo fluorescence images collected by IVIS at 4 h, 8 h, and 24 h showed that there was no major accumulation area of ​​NK-Exos in tumor-free mice, while in breast cancer-bearing mice, NK-Exos were observed to accumulate significantly in the tumor site ( Figure 3 A). At 24 h after NK-Exos injection, major organs (heart, liver, spleen, lung, and kidney) and tumors were collected for in vitro imaging, and the fluorescence signal was displayed using an IVIS imaging system. The results showed that NK-Exos mainly accumulated in the liver in tumor-free mice, while breast cancer tumor-bearing mice showed significantly high uptake and accumulation in both the liver and tumors, and the fluorescence signal intensity in the tumor was higher than that in the liver ( Figure 3 B) These results indicate that NK-Exos have a strong tumor-targeting homing effect, which is of great significance for tumor treatment.

[0101] 3.3 Evaluation of the pathological effects of NK-Exos combined with NK cell injection on major tissues and organs of mice

[0102] The tumor growth curve suggests that the combined intervention of NK-Exos and NK cells has a certain inhibitory effect on tumor growth, while the inhibitory effect of NK cell therapy alone on tumors is not significant ( Figure 4 AD). The in vitro tumor volume and weight collected at the end of treatment showed that the NK-Exos combined with NK cell treatment group had significant differences between the no treatment group and the NK cell treatment group ( Figure 4 EF).

[0103] During the entire treatment period, no significant differences in body weight were observed among the mice in each group ( Figure 5A). H&E staining was performed on the tumors to evaluate the further toxicity of NK-Exos in breast cancer bearing small tumor tissues. H&E staining showed that the tumor apoptosis of mice treated with NK-Exos combined with NK was greater than that of the PBS control group and the NK treatment group ( Figure 5 B).

[0104] In all treatment groups, no obvious tumor metastasis and liver damage were observed in the liver tissue in vitro. Figure 6 A), and the weight of each organ also remained within the normal range ( Figure 6 BF). H&E staining of tissue sections showed that no obvious pathological damage was observed in the liver and other organs among the groups ( Figure 6 G). These data collectively demonstrate that NK-Exos combined with NK cell therapy did not cause significant in vivo toxicity.

[0105] The description of the above embodiments is only used to understand the method and core idea of ​​the present invention. It should be pointed out that, for those skilled in the art, several improvements and modifications can be made to the present invention without departing from the principle of the present invention, and these improvements and modifications will also fall within the scope of protection of the claims of the present invention.

Claims

1. Application of NK cell exosomes combined with NK cells in the preparation of a pharmaceutical composition for the prevention or treatment of triple-negative breast cancer.

2. The use according to claim 1, wherein the NK cell exosomes are administered orally, by suppository, around the lesion, on the lesion surface, topically, intravenously, parenterally, intraperitoneally, intramuscularly, intralesionally, intrathecally, intranasally or subcutaneously; Preferably, the NK cells are administered orally, by suppository, perilesional administration, lesional surface administration, topical application, intravenous administration, parenteral administration, intraperitoneal administration, intramuscular administration, intralesional administration, intrathecal administration, intranasal administration or subcutaneous administration; Preferably, the NK cell exosomes are administered by intravenous injection; Preferably, the NK cells are administered by intravenous injection.

3. The use according to claim 1, wherein the ratio of NK cell exosomes to NK cells is 100 μg: (1×10 4 -1×10 7 )indivual; Preferably, the pharmaceutical composition is used for prevention or treatment according to a course of treatment; Preferably, the treatment course includes one injection of NK cell exosomes and one injection of NK cells as one treatment course; Preferably, the injection of NK cell exosomes and NK cells is performed alternately; Preferably, the time interval between the two injections is 3 days; Preferably, the triple-negative breast cancer is from a human and / or non-human individual; Preferably, the triple-negative breast cancer is from a human.

4. A pharmaceutical composition comprising a preventive or therapeutically effective amount of NK cell exosomes and NK cells in the application according to any one of claims 1 to 3.

5. The pharmaceutical composition according to claim 4, further comprising a pharmaceutical adjuvant; Preferably, the auxiliary agent includes an excipient, a diluent or other liquid solvent, a dispersing aid, a suspending aid, a surfactant, an isotonic agent, a thickener, an emulsifier, a preservative, a solid binder, and a lubricant.

6. A medicine kit, comprising: NK cell exosomes and NK cells in the use according to any one of claims 1 to 3; Preferably, the medicine kit further comprises instructions for use; Preferably, the instructions for use indicate the combined use of NK cell exosomes and NK cells; Preferably, the instructions for use specify whether the NK cell exosomes and NK cells are administered simultaneously, separately, at intervals, or sequentially.

7. Use of NK cell exosomes and NK cells in the application according to any one of claims 1 to 3 in the preparation of a product for inhibiting triple-negative breast cancer cells or tissues and promoting apoptosis of triple-negative breast cancer cells.

8. Application of NK cell exosomes and NK cells in the preparation of products that improve the ability of NK cells to inhibit or kill breast cancer; Preferably, the breast cancer comprises triple-negative breast cancer.

9. A method for inhibiting triple-negative breast cancer cells or tissues in vitro for non-therapeutic purposes, the method comprising the step of applying the pharmaceutical composition of claim 4 or 5 or the pharmaceutical kit of claim 6 to triple-negative breast cancer cells or tissues in vitro.

10. A method for detecting the inhibition rate of triple-negative breast cancer cells, the method comprising: First, DMEM culture medium was added to the RTCA test plate containing triple-negative breast cell lines to determine the background impedance value, and the logarithmic phase cells were collected to adjust the cell suspension to add 8,000 cells to the test plate, and then the test plate was left to stand at room temperature. When the cells sank to the bottom of the test plate, the test plate was placed on a powered test bench for real-time dynamic cell proliferation detection. When the cells proliferated to an Index value of 1, NK cells + NK-Exos were added to the culture wells, and real-time dynamic detection was performed until the growth curve of more than 72 hours after intervention. The inhibition rates at 24 hours, 48 ​​hours, and 72 hours were calculated, and the cell effect curves under the action of NK-Exos and NK cells were analyzed; Collect logarithmic phase cells and adjust the cell suspension to 8000 cells and add them to the well plate, place it in the incubator, and when the cell fusion rate is 60% to 70%, add NK cells + NK-Exos to the culture wells. At 48 hours after the intervention, add CCK-8 detection reagent to the wells, incubate at 37°C for 4 hours, and measure the absorbance at 450nm with a microplate reader to calculate the cell inhibition rate: inhibition rate (%) = (control group OD value - experimental group OD value / control group OD value) × 100%; Preferably, the amount of NK cells + NK-Exos added is 1×10 4 NK cells + 10 μg NK-Exo / well.

Citation Information

Cited By

  • Application of exosome as irreversible ablation auxiliary preparation

    CN121059643A